Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

All-trans-retinoic acid in acute promyelocytic leukemia

Article Abstract:

All-trans-retinoic acid appears to be significantly better than chemotherapy in the treatment of acute promyelocytic leukemia. Researchers randomly assigned 346 patients with this type of leukemia to receive all-trans-retinoic acid or chemotherapy with daunorubicin and cytarabine. Remission rates were 69% in the chemotherapy group and 72% in the all-trans-retinoic group. Those with the lowest 1-, 2-, and 3-year survival rates were those who received chemotherapy alone but no maintenance treatment with all-trans-retinoic acid following remission. Patients who received all-trans-retinoic acid had significantly higher survival rates.

Author: Shepherd, Lois, Schiffer, Charles A., Appelbaum, Frederick R., Andersen, Janet W., Bloomfield, Clara D., Wiernik, Peter H., Tallman, Martin S., Rowe, Jacob M., Feusner, James H., Ogden, Angela, Willman, Cheryl
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
Care and treatment, Tretinoin, Acute leukemia, Promyelocytic, Acute myelocytic leukemia

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Positron-emission tomography and assessment of cancer therapy

Article Abstract:

Positron-emission tomography (PET) is a noninvasive imaging technique that exploits the unique decay of positron-emitting isotopes of oxygen, carbon, nitrogen and fluorine for development of diagnostically useful biological compounds available for PET to provide a functional or metabolic assessment of normal tissues or disease conditions. PET is evaluated for its ability to predict response or lack of response at very early stage in the course of treatment.

Author: Cheson, Bruce D., Juweid, Malik E.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
Science & research, HEALTH SERVICES, Medical and Diagnostic Laboratories, Cancer Diagnosis, Research, Usage, Cancer, PET imaging, Positron emission tomography

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Article Abstract:

Fludarabine may be effective in treating chronic lymphocytic leukemia that does not respond to chlorambucil. In a study of 509 patients, fludarabine resulted in higher response rates and longer remissions but did not improve overall survival rates.

Author: Larson, Richard A., Rai, Kanti R., Peterson, Bercedis L., Applebaum, Frederick R., Kolitz, Jonathan, Elias, Laurence, Shepherd, Lois, Hines, John, Threatte, Gregory A., Cheson, Bruce D., Schiffer, Charles A.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Chemotherapy, Fludarabine, Chronic lymphocytic leukemia

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, United States
Similar abstracts:
  • Abstracts: Prevalence, Donation Practices, and Risk Assessment of Blood Donors With Hemochromatosis. Demographic determinants of hepatitis C virus seroprevalence among blood donors
  • Abstracts: Bone marrow transplantation in patients with thalassemia. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
  • Abstracts: Self-referral of patients for electron-beam computed tomography to screen for coronary artery disease. Lack of correlation between psychological factors and subclinical coronary artery disease
  • Abstracts: Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort. Relation of lean body mass to health-related quality of life in persons with HIV
  • Abstracts: Alternative Medicine Meets Science. Genetics and genomics for clinicians. Prepublication Release of Medical Research
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.